Mirabegron: The most promising adipose tissue beiging agent
Open Access
- 2 March 2021
- journal article
- review article
- Published by Wiley in Physiological Reports
- Vol. 9 (5), e14779
- https://doi.org/10.14814/phy2.14779
Abstract
Accumulation of white adipose tissue (WAT) underlies the obesity epidemic, leading to current therapeutic techniques that are being investigated for their ability to activate/"beige" this tissue. Adipose tissue (AT) beiging has been reported through intermittent cold exposure (CE), exercise, and beta 3-Adrenergic Receptor (beta 3AR) agonists. But how AT beiging can help in the treatment of metabolic disorders like obesity and type 2 diabetes (T2D) remains largely unexplored. This review summarizes recent research on the use of beta 3AR agonist, mirabegron (Myrbetriq (R)), in stimulating beiging in AT. Researchers have only recently been able to determine the optimal therapeutic dose of mirabegron for inducing beiging in subcutaneous/inguinal WAT, where the benefits of AT activation are evident without the undesired cardiovascular side effects. To determine whether the effects that mirabegron elicits are metabolically beneficial, a comparison of the undisputed findings resulting from intermittent CE-induced beiging and the disputed findings from exercise-induced beiging was conducted. Given the recent in vivo animal and clinical studies, the understanding of how mirabegron can be metabolically beneficial for both lean and obese individuals is more clearly understood. These studies have demonstrated that circulating adipokines, glucose metabolism, and lipid droplet (LD) size are all positively affected by mirabegron administration. Recent studies have also demonstrated that mirabegron has similar outcomes to intermittent CE and displays more direct evidence for beiging than those produced with exercise. With these current findings, mirabegron is considered the most promising and safest beta 3AR agonist currently available that has the potential to be used in the therapeutic treatment of metabolic disorders, and future studies into its interaction with different conditions may prove to be useful as part of a treatment plan in combination with a healthy diet and exercise.Funding Information
- Natural Sciences and Engineering Research Council of Canada (CRDPJ/494077‐16)
This publication has 41 references indexed in Scilit:
- Common and distinct regulation of human and mouse brown and beige adipose tissues: a promising therapeutic target for obesityProtein & Cell, 2017
- Breaking BAT: can browning create a better white?Journal of Endocrinology, 2015
- Exercise Effects on White Adipose Tissue: Beiging and Metabolic AdaptationsDiabetes, 2015
- Voluntary physical activity prevents insulin resistance in a tissue specific mannerPhysiological Reports, 2015
- Activation of Human Brown Adipose Tissue by a β3-Adrenergic Receptor AgonistCell Metabolism, 2015
- Interleukin-6 deficiency causes tissue-specific changes in signaling pathways in response to high-fat diet and physical activityPhysiological Reports, 2014
- Safety and tolerability of the β 3 ‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised Phase III trials and of a 1‐year randomised Phase III trialInternational Journal of Clinical Practice, 2014
- A phase II dose-ranging study of mirabegron in patients with overactive bladderInternational Urogynecology Journal, 2013
- A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesisNature, 2012
- Tissue functions mediated by beta(3)-adrenoceptors-findings and challenges.Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 2010